According to filings with the U.S. Securities and Exchange Commission, Purgo Scientific is raising up to $3,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Michael Benjamin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Purgo Scientific
Purgo Scientific is a medical device company developing a novel method for targeted therapeutic drug delivery. While there are many applications for this method, the initial goal is to treat and prevent biofilm-related surgical site infections that compromise indwelling devices such as orthopedic implants. Targeted drug delivery against biofilms with local, high dose concentrations of antibiotic have a better chance at treating these infections than other therapies. In the United States alone, each year this problem affects as many as 300,000 people and costs the healthcare system up to $10 billion. The ultimate goal for our device is to extend its application beyond the eradication of biofilm-caused infections, and to treat any health issue that benefits from precise medicine delivery, including pain and oncology applications.

To learn more about Purgo Scientific, visit http://purgoscientific.com/
Company Linkedin Page: https://www.linkedin.com/company/purgo-scientific/

Contact:
Michael Benjamin, Chief Executive Officer
702-499-7404

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.